Fennec Pharmaceuticals Inc.
FENC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001211583
In the last 90 days, Fennec Pharmaceuticals Inc. insiders filed 0 open-market purchases and 5 sales; 105 institutions reported holding it in 13F filings for Q2 2026, worth $175.1M in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Fennec Pharmaceuticals Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Of which not filed for Q2 2024 | Q2 2024 | Change |
|---|---|---|---|---|
| Holders | 65 | 1 | 64 | 0 |
| Shares | 14.5M | 35.4K | 14.4M | −91.9K (−0.6%) |
| Value | $161.1M | $393.2K | $87.7M | −$73.0M (−45.4%) |
1 institution that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (17)
Institutions that held Fennec Pharmaceuticals Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Winton Group Ltd | 67,005 | $409.4K | 0.03% |
| Verition Fund Management LLC | 33,738 | $206.1K | 0.00% |
| Sherbrooke Park Advisers LLC | 28,370 | $173.3K | 0.03% |
| Hillsdale Investment Management Inc. | 24,491 | $149.6K | 0.01% |
| State of Wisconsin Investment Board | 13,034 | $79.6K | 0.00% |
| Corebridge Financial, Inc. | 12,610 | $77.0K | 0.00% |
| Franklin Resources Inc | 12,469 | $76.2K | 0.00% |
| Pinnacle Wealth Planning Services, Inc. | 12,289 | $75.1K | 0.01% |
| Manufacturers Life Insurance Company, The | 11,310 | $69.1K | 0.00% |
| Mirae Asset Global ETFs Holdings Ltd. | 9,762 | $59.6K | 0.00% |
| Acadian Asset Management LLC | 8,086 | $49.0K | 0.00% |
| Lazard Asset Management LLC | 1,740 | $10.0K | 0.00% |
| GWM Advisors LLC | 1,328 | $8.12K | 0.00% |
| Jones Financial Companies LLLP | 650 | $3.97K | 0.00% |
| The PNC Financial Services Group, Inc. | 112 | $684 | 0.00% |
| Nisa Investment Advisors, LLC | 69 | $422 | 0.00% |
| Covestor Ltd | 77 | $0 | 0.00% |
Sold out (17)
Institutions that held Fennec Pharmaceuticals Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| AIGH Capital Management LLC | 570,332 | $6.34M |
| Essex Investment Management Co LLC | 144,218 | $1.60M |
| Renaissance Technologies LLC | 139,900 | $1.56M |
| Legato Capital Management LLC | 57,121 | $635.2K |
| Citadel Advisors LLC | 48,714 | $541.7K |
| 683 Capital Management, LLC | 48,108 | $535.0K |
| Arrowstreet Capital, Limited Partnership | 39,909 | $444.0K |
| Susquehanna International Group, LLP | 22,599 | $251.3K |
| Jump Financial, LLC | 19,000 | $211.3K |
| Worth Venture Partners, LLC | 10,327 | $114.8K |
| Cubist Systematic Strategies, LLC | 10,162 | $113.0K |
| American International Group, Inc. | 8,944 | $99.5K |
| Metropolitan Life Insurance Co | 1,003 | $11.2K |
| Point72 (DIFC) Ltd | 256 | $2.85K |
| Cornerstone Planning Group LLC | 66 | $610 |
| Toronto Dominion Bank | 25 | $278 |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 3 | $33 |
Not filed for Q2 2024 yet (1)
Institutions that held Fennec Pharmaceuticals Inc. at the end of Q1 2024 and haven't filed a 13F for Q2 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Eudaimonia Advisors LLC | 35,359 | $393.2K |